June 2024
1. HEY JA, Yu JY, Abushakra S, Schaefer JF, et al
   Analysis of Cerebrospinal Fluid, Plasma beta-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model.
   Drugs. 2024 Jun 20. doi: 10.1007/s40265-024-02068.
   

   >> Share

   
   
2. HEY JA, Abushakra S, Blennow K, Reiman EM, et al
   Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.
   Drugs. 2024 Jun 20. doi: 10.1007/s40265-024-02067.
   

   >> Share

   
   September 2023
3. CUMMINGS JL, Osse AML, Kinney JW
   Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification.
   Drugs. 2023 Sep 20. doi: 10.1007/s40265-023-01938.
   

   >> Share

   
   April 2023
4. CUMMINGS J
   Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics.
   Drugs. 2023 Apr 15. doi: 10.1007/s40265-023-01858.
   

   >> Share

   
   March 2023
5. HOY SM
   Lecanemab: First Approval.
   Drugs. 2023;83:359-365.
   

   >> Share

   
   April 2022
6. SCHIFANO F, Catalani V, Sharif S, Napoletano F, et al
   Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals.
   Drugs. 2022 Apr 2. pii: 10.1007/s40265-022-01701.
   

   >> Share

   
   August 2021
7. DHILLON S
   Aducanumab: First Approval.
   Drugs. 2021;81:1437-1443.
   

   >> Share

   
   July 2021
8. JI C, Sigurdsson EM
   Current Status of Clinical Trials on Tau Immunotherapies.
   Drugs. 2021;81:1135-1152.
   

   >> Share

   
   March 2020
9. SCOTT LJ
   Lemborexant: First Approval.
   Drugs. 2020;80:425-432.
   

   >> Share

   
   
10. SYED YY
    Sodium Oligomannate: First Approval.
    Drugs. 2020;80:441-444.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share